Clinical Trials Browser

Phase 2 × sotigalimab × Dermatologic × Clear all

NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Phase 2 Terminated

45 enrolled 14 charts

Melanoma, Neoplasms, Skin Neoplasms